Blair William & Co. IL Reduces Position in Amgen Inc.

Institutional investor trims stake in biotech giant Amgen

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Blair William & Co. IL reduced its position in Amgen Inc. (NASDAQ:AMGN) by 2.8% during the third quarter. The institutional investor now owns 162,239 shares of the medical research company's stock, valued at $45,784,000.

Why it matters

Amgen is a major player in the biotechnology industry, and changes in institutional ownership of its stock can provide insights into market sentiment and expectations around the company's performance.

The details

Blair William & Co. IL, an institutional investor, sold 4,654 shares of Amgen stock during the third quarter, reducing its total position to 162,239 shares. The firm cited the filing with the Securities and Exchange Commission. Amgen is a leading biopharmaceutical company focused on developing and delivering innovative human therapeutics.

  • The position reduction occurred during the third quarter of the year.

The players

Blair William & Co. IL

An institutional investor that manages a portfolio of investments, including shares of Amgen Inc.

Amgen Inc.

A global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Blair William & Co. IL's position in Amgen may indicate a shift in market sentiment or a strategic portfolio adjustment by the institutional investor. However, Amgen remains a major player in the biotechnology industry, and changes in institutional ownership are common as investors manage their portfolios.